Biological mechanisms underlying inter‐individual variation in factor VIII clearance in haemophilia

Por Turecek, Peter L., Johnsen, Jill M., Pipe, Steven W., O'Donnell, James S.
Publicado no Haemophilia (2020)

Polyethylene Glycol Exposure with Antihemophilic Factor (Recombinant), PEGylated (rurioctocog alfa pegol) and Other Therapies Indicated for the Pediatric Population: History and Sa...

Por Stidl, Reinhard, Denne, Michael, Goldstine, Jimena, Kadish, Bill, Korakas, Katherine I., Turecek, Peter L.
Publicado no Pharmaceuticals (Basel) (2018)

Origins, Development, Current Challenges and Future Directions with Activated Prothrombin Complex Concentrate for the Treatment of Patients with Congenital Haemophilia with Inhibit...

Por Brackmann, Hans H., Schramm, Wolfgang, Oldenburg, Johannes, Cano, Viridiana, Turecek, Peter L., Négrier, Claude
Publicado no Hamostaseologie (2020)

Anti-ADAMTS13 IgG autoantibodies present in healthy individuals share linear epitopes with those in patients with thrombotic thrombocytopenic purpura

Por Grillberger, Rana, Casina, Veronica C., Turecek, Peter L., Zheng, X. Long, Rottensteiner, Hanspeter, Scheiflinger, Friedrich
Publicado em 2014

A bio-inspired method for direct measurement of local wall shear rates with micrometer localization using the multimeric protein von Willebrand factor as sensor molecule

Por Bonazza, Klaus, Scheichl, Bernhard, Frank, Johannes, Rottensteiner, Hanspeter, Schrenk, Gerald, Friedbacher, Gernot, Turecek, Peter L., Scheiflinger, Friedrich, Allmaier, Günter
Publicado no Biomicrofluidics (2017)

High-dose factor VIII inhibits factor VIII–specific memory B cells in hemophilia A with factor VIII inhibitors

Por Hausl, Christina, Ahmad, Rafi U., Sasgary, Maria, Doering, Christopher B., Lollar, Pete, Richter, Günter, Schwarz, Hans Peter, Turecek, Peter L., Reipert, Birgit M.
Publicado em 2005

Preclinical safety and efficacy of a new recombinant FIX drug product for treatment of hemophilia B

Por Dietrich, Barbara, Schiviz, Alexandra, Hoellriegl, Werner, Horling, Frank, Benamara, Karima, Rottensteiner, Hanspeter, Turecek, Peter L., Schwarz, Hans Peter, Scheiflinger, Friedrich, Muchitsch, Eva-Maria
Publicado no Int J Hematol (2013)

Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura

Por Ferrari, Silvia, Palavra, Kristina, Gruber, Bernadette, Kremer Hovinga, Johanna A., Knöbl, Paul, Caron, Claudine, Cromwell, Caroline, Aledort, Louis, Plaimauer, Barbara, Turecek, Peter L., Rottensteiner, Hanspeter, Scheiflinger, Friedrich
Publicado em 2014

Strategies for recombinant Furin employment in a biotechnological process: complete target protein precursor cleavage

Por Preininger, Alexandra, Schlokat, Uwe, Mohr, Gabriele, Himmelspach, Michèle, Stichler, Veronika, Kyd-Rebenburg, Astrid, Plaimauer, Barbara, Turecek, Peter L., Schwarz, Hans-Peter, Wernhart, Waltraud, Fischer, Bernhard E., Dorner, Friedrich
Publicado em 1999

Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19

Por Turecek, Peter L., Peck, Rachel C., Rangarajan, Savita, Reilly-Stitt, Christopher, Laffan, Michael A., Kazmi, Rashid, James, Izabela, Dushianthan, Ahilanandan, Schrenk, Gerald, Gritsch, Herbert, Ewenstein, Bruce M., Mellgard, Bjorn, Erdlenbruch, Wolfhard, Jain, Nisha, Binder, Nikolaus B., Mumford, Andrew D.
Publicado no Thromb Res (2021)

Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial

Por Mannucci, Pier Mannuccio, Kempton, Christine, Millar, Carolyn, Romond, Edward, Shapiro, Amy, Birschmann, Ingvild, Ragni, Margaret V., Gill, Joan Cox, Yee, Thynn Thynn, Klamroth, Robert, Wong, Wing-Yen, Chapman, Miranda, Engl, Werner, Turecek, Peter L., Suiter, Tobias M., Ewenstein, Bruce M.
Publicado em 2013